LOAMU
CASC

Lombard Odier Asset Management (USA)’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-88,381
Closed -$1.45M – 209
2015
Q3 		$1.45M Buy
88,381
+38,381
+77% +$787K 0.13% 150
2015
Q2 		$1.12M Buy
+50,000
New +$791K 0.08% 160

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s CASC Position: Q4 2015 in Review

Lombard Odier Asset Management (USA) sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 88,381 shares — an estimated $1.45M sold.

Lombard Odier Asset Management (USA) first reported a position in CASC in Q2 2015 and held it in 2 quarters. The position peaked at $1.45M in Q3 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

  • Lombard Odier Asset Management (USA) reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 88,381 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $1.45M.
  • Lombard Odier Asset Management (USA) first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Lombard Odier Asset Management (USA)'s Cascadian Therapeutics, Inc. position peaked at $1.45M in Q3 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2015, filed 16 Feb 2016.